2002
A Phase II Randomized Study of the Virologic and Immunologic Effect of Zidovudine + Stavudine versus Stavudine Alone and Zidovudine + Lamivudine in Patients with >300 CD4 Cells Who Were Antiretroviral Naive (ACTG 298)
Pollard RB, Tierney C, Havlir D, Tebas P, Fox L, Smeaton L, Richman D, Friedland GH. A Phase II Randomized Study of the Virologic and Immunologic Effect of Zidovudine + Stavudine versus Stavudine Alone and Zidovudine + Lamivudine in Patients with >300 CD4 Cells Who Were Antiretroviral Naive (ACTG 298). AIDS Research And Human Retroviruses 2002, 18: 699-704. PMID: 12167276, DOI: 10.1089/088922202760072311.Peer-Reviewed Original ResearchConceptsCD4 cell countStandard of careD4TViral loadWeek 12Copies/Cell countMedian baseline viral loadPhase II Randomized StudyD4T armDual nucleoside therapyAntiretroviral-naive patientsBaseline viral loadWeeks of monotherapyViral load reductionTreatment of patientsDevelopment of multidrugAntiretroviral-NaiveAntiviral suppressionNaive patientsCD4 cellsImmunologic effectsHIV infectionRandomized studyNucleoside therapy
2000
In Vivo Antagonism with Zidovudine plus Stavudine Combination Therapy
Havlir D, Tierney C, Friedland G, Pollard R, Smeaton L, Sommadossi J, Fox L, Kessler H, Fife K, Richman D. In Vivo Antagonism with Zidovudine plus Stavudine Combination Therapy. The Journal Of Infectious Diseases 2000, 182: 321-325. PMID: 10882616, DOI: 10.1086/315683.Peer-Reviewed Original ResearchConceptsCD4 cell countD4TCell countD4T armD4T monotherapyWeeks of therapyHuman immunodeficiency virusCopies/mLGreater antiviral activityT monotherapyHIV RNACurrent regimenImmunodeficiency virusPharmacologic antagonismCombination therapyMean reductionZidovudineAntiviral activityVivo antagonismProgressive declinePatientsCells/DdIIntracellular levelsTherapy